靶向药|当肿瘤也学会“百花齐放”,以精准著称的靶向药该如何破敌?( 五 )


[31].Arshad J, Roberts A, Ahmed J, et al. Utility of circulating tumor DNA in the management of patients with GI stromal tumor: analysis of 243 patients[J]. JCO Precision Oncology, 2020, 4: 66-73.
[32].Smith B D, Kaufman M D, Lu W P, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants[J]. Cancer cell, 2019, 35(5): 738-751. e9.
[33].Schneeweiss M, Peter B, Bibi S, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis[J]. Haematologica, 2018, 103(5): 799-809.
[34].Blay J Y, Serrano C, Heinrich M C, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. The Lancet Oncology, 2020.
[35].《CSCO胃肠间质瘤诊疗指南》
[36].Patrick Sch?ffski, et al. Ripretinib demonstrated activity across all KIT/PDGFRA mutations in patients with fourth-line advanced gastrointestinal stromal tumor: Analysis from the phase 3 INVICTUS study. 2020 CTOS Virtual Meeting , 2020.
靶向药|当肿瘤也学会“百花齐放”,以精准著称的靶向药该如何破敌?
文章图片


本文作者 | BioTalker

推荐阅读